Abstract
This study documents changes in prostate cancer screening patterns in a defined medical practice. 1 Wallner L.P. Hsu J.W. Loo R.K. Palmer-Toy D.E. Schottinger J.E. Jacobsen S.J. Trends in prostate-specific antigen screening, prostate biopsies, urology visits, and prostate cancer treatments from 2000 to 2012. Urology. 2015; 86: 498-505 Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar Since 2008, there is a decline especially among older men without a change in the rate of prostate cancer diagnosis. The pattern suggests that the doctors in the study became more discriminating in their decision to screen. This may be a model for the teaching about and use of prostate cancer screening. Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012UrologyVol. 86Issue 3PreviewTo determine whether the rates of prostate-specific antigen (PSA) screening, related biopsies and subsequent prostate cancer utilization decreased between 2000 and 2012 in a large, managed care organization. Full-Text PDF ReplyUrologyVol. 86Issue 3PreviewWe thank Drs. Brawley1 and Loeb2 for their thoughtful comments about screening for prostate cancer and the results reported here at Kaiser Permanente Southern California. The evidence about prostate-specific antigen screening for prostate cancer is controversial, particularly in an age where risk stratification is inexact. However, there is little controversy regarding when prostate cancer screening is no longer beneficial, and as such, we have chosen to focus our efforts in reducing unnecessary overscreening, overdiagnosis, and overtreatment in older men. Full-Text PDF Editorial CommentUrologyVol. 86Issue 3PreviewIn 2008, the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening for men aged >75 years and extended this to men of all ages in a 2011 draft recommendation that was finalized in 2012.1 Similar recommendations against PSA were issued by the Canadian Preventive Health Task Force in 2014.2 These guidelines have generated significant controversy and contrast with the recommendations of numerous professional societies for shared decision making about PSA. Full-Text PDF
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call